Results 171 to 180 of about 12,153 (191)
Some of the next articles are maybe not open access.
UGT1A1 genotyping and neutropenia risk
The Lancet Oncology, 2007High-dose irinotecan treatment should be decided according to the patient’s UGT1A1 genotype, but for the common therapeutic range of 100–125 mg/m2, this pharmacogenetic approach might be a waste of money, suggests a metaanalysis (J Natl Cancer Inst, published online August 28, 2007; DOI:10.1093/ jnci/djm115).
openaire +1 more source
Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype
Int. Journal of Clinical Pharmacology and Therapeutics, 2004The metabolism of acetaminophen (paracetamol) is thought to be altered in patients with Gilbert's syndrome (GS), a chronic unconjugated hyperbilirubinemia. The underlying cause of GS is a polymorphism in the promotor region of the uridine diphosphate glucuronosyltransferase isoform 1A1 gene (UGT1A1*28), its encoded enzyme being responsible for the ...
S K, Rauchschwalbe +3 more
openaire +2 more sources
[Role of UGT1A1*28 and UGT1A1*6 for irinotecan-induced adverse drug reaction].
Gan to kagaku ryoho. Cancer & chemotherapy, 2008Irinotecan is widely used in the treatment of colorectal, gastric, and lung cancers. However, adverse drug reactions such as severe diarrhea and neutropenia limit the dose of this drug. Irinotecan is metabolized by carboxylesterase to form an active metabolite, 7-ethyl-10-hydroxycamptothecin(SN-38), which in turn is subsequently conjugated by UGT ...
Masahide, Onoue, Ken-ichi, Inui
openaire +1 more source
OV-A-2Inducibility of UGT1A1 mrna is dependent on UGT1A1⁎28 genotype
Clinical Pharmacology & Therapeutics, 2006I CASCORBI +4 more
openaire +1 more source
Towards UGT1A1 guided irinotecan dosing
European Journal of Human Genetics, 2023openaire +2 more sources
Rational design of a highly selective UGT1A1 probe and its application in drug discovery
Sensors and Actuators B: Chemical, 2022Lei Liang, Xue Qiao, Min Ye
exaly